Day 1 - Wednesday, 21 June 2017
Meeting category
Date(s)
21 Jun 2017 - 23 Jun 2017
Location
Lisbon,
Portugal
Organizer
Platinum Level Support
Sponsor logos
International Workshop on HIV & Hepatitis Co-infection 2017
Related Enduring Materials
Enduring Materials
Program
Pre-workshop Education Course - Part I -
Mark Nelson, MA, MBBS, FRCP
Acute HCV in HIV: Diagnosis and management (not available)
Chelsea and Westminster Hospital / Imperial College Medical School, United Kingdom
Management of HCV in intravenous drug users: special considerations
Hepatitis E in HIV
Pre-workshop Education Course - Part II -
News on hepatitis delta and HIV infections
EASL highlights 2017
Session 1: Updates in HBV -
New insights in management of HIV/HBV co-infected patients
New markers / new uses for old markers for hepatitis B (Not available)
Geoffrey Dusheiko, MD
Royal Free Hospital, UK
Session 2: Clinical management of patients on DAA therapy -
Mark Nelson, MA, MBBS, FRCP
Special considerations before / during / after DAA therapy
Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Pro stance
Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Con stance (Not available)
Chelsea and Westminster Hospital / Imperial College Medical School, United Kingdom
Session 3: Future directions of ARVs -
Virologist's perspective
Clinician's perspective (Not available)
Pharmacologist's perspective
Day 2 - Thursday, 22 June 2017
Session 4: Special issues in HCV treatment -
Are there any special populations in treatment of HCV left?
Abstract presentations
Relapse or reinfection of hepatitis C after direct acting antiviral treatment: unravelled by phylogenetic analysis. Results from the Spanish GEHEP-004 cohort.
L. Cuypers
HCV chronic infection treatment with DAA: who are the patients that are not achieving sustained virologic response?
R. Valente
HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study
D. Seixas
Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1
P. Buggish
Clinical evolution of porphyria cutanea tarda (PCT) in HCV monoinfected and HIV/HCV co-infected patients after viral eradication with direct acting agents (DAA)
P. Rodriguez Cortes
Session 5: Transplantations and other hepatitis viruses -
Abstract presentations
Acute hepatitis A outbreak among men who have sex with men in Milan: the role of HIV co-infection.
M. Merli
Outbreak of hepatitis A in men who have sex with men in 2017 - Experience in an infectious diseases department, Hospital de Curry Cabral - CHLC, Lisbon, Portugal
A.R. Garrote
Direct acting antiviral treatment for HCV in safety net settings: Provider and HIV/HCV co-infected patient preferences
M. Peters
Session 6: Best of posters -
No video available
Session 7: Post SVR considerations -
Non liver and survival benefits of SVR in HCV
Case based debate: Is HCC increased with DAA therapy? Pro stance
Case based debate: Is HCC increased with DAA therapy? Con stance
Session 8: Liver complication (hepatitis related) -
Abstract presentations
Hepatic steatosis AND Lipid proFile evolution After Hepatitis C treatment in hcv/hiv coinfected patients
J. Méndez
Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia
E. Dolmazashvili
Hepatitis co-infections and HBV vaccination status among people living with HIV in Germany - Data from a hepatitis screening in the German HIV-1 seroconverter cohort (Not available)
D. Schmidt
Session 9: Challenges for the next year -
Nikoloz Chkhartishvili, MD, MS, PhD
HCV elimination program in Georgia: Successes and challenges
Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia
What challenges remain in viral hepatitis
Overview
Welcome
We are very pleased with the successful 13th edition of the International Workshop on HIV & Hepatitis Co-infection, held on 21 - 23 June 2017 in Lisbon, Portugal.
This year’s edition continued to focus on developments in basic science, emerging therapies for Hepatitis B and clinical management for Hepatitis C after cure. It emphasized translational research and best practices in the clinical management of Hepatitis and HIV co-infection.
We would also like to dedicate our gratitude to our sponsors, ViiV Healthcare, Gilead, MSD, and Mylan for their support that made this event possible.
The 2017 Program Committee
Program Committee
Committees
Organizing Committee
The members of the Organizing Committee (OC) are a group of carefully selected experts and inspirational leaders in their respective fields. They come together on a frequent basis to discuss the scientific program of the workshop, identify interesting topics and candidate speakers and review all submitted abstracts.
Scientific Committee
The members of Scientific Committee are hand-picked by the OC and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
Sanjay Bhagani - Royal Free Hospital London, United Kingdom
Raffaele Bruno - University of Pavia, Italy
Andy Hoepelman - UMC Utrecht, Netherlands
Patrick Ingiliz - Medical Center for Infectious Diseases, Germany
Arthur Kim - Massachusetts General Hospital, USA
Marina Klein - McGill University Health Centre, Canada
Sharon Lewin - Monash University Alfred Hospital, Australia
Stefan Mauss - Center for HIV and Hepatogastroenterology, Germany
Juan A. Pineda - Hospital de Valme, Spain
Stanislas Pol - Hôpital Cochin, France
Giuliano Rizzardini - University of Milan,Italy
Dominique Salmon - Hopital Cochin, France
Ulrich Spengler - University of Bonn, Germany
Cristina Tural - Hospital Germans Trias i Pujol, Spain
Support
Endorsers
